ITM’s path toward a potential U.S. approval for ¹⁷⁷Lu-edotreotide has hit a regulatory delay, but the most important part of the FDA’s decision may be what the agency did not question.
On August 10,ITM Isotope Technologies Munich announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration for ITM-11, its investigational lutetium-177 radiopharmaceutical therapy for gastroenteropancreatic neuroendocrine tumors. According to the company, the FDA identified no concerns with the clinical or nonclinical data package, raised no safety issues and requested no additional clinical or nonclinical studies. Instead, the CRL cited Chemistry, Manufact
uring and Controls issues, along with items related to inspections of third-party commercial facilities.
ITM CEO Dr. Andrew Cavey emphasized that the underlying therapeutic thesis remains unchanged.
“Our confidence in ITM-11’s therapeutic potential has not wavered, and we are committed to working closely with the FDA and our partners to address the items outlined in the CRL,” Cavey said. “Our pivotal COMPETE trial data package stands.”
For ITM, that distinction is important because it suggests the application has encountered a manufacturing and execution problem rather than a clinical one. But for the wider radiopharmaceutical industry, the implications are broader. ITM is now the latest in a series of companies to reach the FDA with a clinically supported product only to discover that commercial manufacturing readiness can become the final—and potentially decisive—regulatory hurdle.
Telix Pharmaceuticals faced a similar issue with Zircaix in 2025, while Lantheus followed with another manufacturing-related CRL in June 2026. The details differ in each case, but together they point toward an increasingly visible pressure point across radiopharma: the industry’s ability to translate strong clinical programs into manufacturing systems that are scalable, reproducible and capable of consistently satisfying FDA expectations.
Telix’s experience offers one of the clearest examples of how difficult that transition can be. In August 2025, the company received a Complete Response Letter for TLX250-CDx, now known as Zircaix, its zirconium-89 PET imaging agent for clear-cell renal cell carcinoma. The regulatory setback was not driven by failure of the ZIRCON Phase 3 study, which had met its primary and secondary endpoints. Instead, the FDA raised CMC deficiencies and sought additional information demonstrating comparability between the product used during clinical development and material produced through Telix’s scaled-up commercial manufacturing process. Two contracted manufacturing and supply-chain providers also received FDA Form 483 observations requiring remediation.
At the time, Telix CEO Dr. Christian Behrenbruch framed the issue as something larger than a single product.
“Like many radiopharmaceuticals, it has a complex supply chain, and as the field advances this creates new challenges around the regulatory framework applied to these products,” Behrenbruch said.
Less than a year later, Lantheus encountered an even more direct example of third-party manufacturing exposure. In June, the FDA issued a CRL for LNTH-2501, the company’s gallium-68 edotreotide PET imaging kit for neuroendocrine tumors, because of unresolved manufacturing-related conditions at a third-party facility responsible for drug product manufacturing. Lantheus said the FDA had identified no concerns with the submitted clinical data, safety or efficacy.
“The feedback received from the FDA relates solely to our third-party manufacturer, and not to the clinical performance of the product,” Lantheus CEO Mary Anne Heino said. “We are working closely with our partner and the Agency to address these facility manufacturing-related conditions and advance the program.”
Now ITM has received a CRL with a similarly important distinction. Its COMPETE clinical package remains intact, but the approval process cannot proceed until CMC and third-party commercial facility issues are addressed.
These three cases are not evidence of a new FDA policy, nor are the underlying deficiencies identical. But they do suggest that manufacturing is moving from a largely operational discussion to a central regulatory and commercial risk for the sector.
For much of the past several years, the radiopharmaceutical market has been defined by clinical innovation and isotope supply. Investors and drug developers have focused on which targets are most promising, whether alpha emitters can outperform beta emitters in certain settings, how quickly radiopharmaceutical therapies can move into earlier lines of treatment and whether enough Lu-177, Ac-225 and other isotopes can be produced to meet future demand.
Those questions remain important, but the industry is entering a more mature phase. A growing number of programs are now approaching commercialization, and that means the infrastructure supporting them is being subjected to a far more demanding test.
Clinical-scale manufacturing and commercial-scale manufacturing are not the same thing. As programs grow, production volumes increase, processes change, new suppliers and facilities are introduced, analytical methods evolve and quality systems must support greater complexity. Regulators must be satisfied that the product ultimately delivered to patients is sufficiently consistent with the product that generated the clinical data supporting approval.
Telix’s Zircaix experience illustrates the challenge particularly well. The scientific program had succeeded, but the FDA wanted stronger evidence that the scaled-up commercial manufacturing process would produce a drug comparable to the one studied in ZIRCON. That is why these manufacturing issues should not be dismissed as back-office operational problems. At this stage of the sector’s development, they are commercialization problems.
Radiopharmaceuticals bring an additional layer of difficulty because their manufacturing and distribution systems are inherently more constrained than those of many conventional pharmaceuticals. Radioactive decay means production, release and delivery occur against the clock. The manufacturing network must coordinate isotope production, precursor availability, radiolabeling, purification, analytical testing, batch release, packaging, transportation and patient administration within narrow time windows. The same facilities must also operate under demanding pharmaceutical quality standards while managing radiation safety, shielding, contamination controls and radioactive waste.
The result is that manufacturing is unusually intertwined with the product itself.
For radiopharmaceutical companies, the challenge is therefore not simply finding a facility with available hot-cell space or the right radioactive material licenses. Commercial readiness depends on validated processes, analytical capability, quality systems, documentation, inspection preparedness, experienced personnel and the ability to reproduce a product at scale.
The recent regulatory setbacks illustrate what happens when one part of that chain is not fully ready when the clinical program reaches the FDA.
The role of external manufacturing partners is particularly important because relatively few radiopharmaceutical developers control their entire supply chain. Most depend on networks that may include isotope producers, precursor suppliers, CDMOs, testing laboratories, nuclear pharmacies, packaging operations and specialized logistics providers. That model allows companies to advance programs without carrying the full capital burden of building every capability internally, but it also creates a fundamental dependency: a sponsor may outsource production, but it cannot outsource responsibility for regulatory performance.
The Lantheus case made that point directly. The company’s own description of the CRL indicated that the issue resided with its third-party manufacturer, yet the consequence was still a delay to Lantheus’ product.
ITM’s disclosure carries a similar warning because the CRL specifically cites third-party commercial facility inspection-related items. Telix, meanwhile, encountered Form 483 observations at two contracted manufacturing and supply-chain providers in addition to the comparability questions surrounding commercial production.
For developers choosing manufacturing partners, that changes the standard by which those partners should be evaluated. Capacity alone is no longer enough. A manufacturer may be capable of handling Lu-177, Ga-68, Zr-89 or another isotope and still not have the regulatory infrastructure necessary to support a commercial product. In a market where a facility issue can delay approval of an otherwise successful drug, inspection history, quality culture and regulatory execution become economically significant capabilities.
That has major implications for the radiopharmaceutical CDMO and manufacturing market. Much of the sector’s infrastructure conversation has focused on physical capacity: the number of hot cells being built, the number of new production facilities coming online, which isotopes those facilities can handle and how much incremental output they can provide. But as more late-stage programs approach the FDA, the industry may begin to distinguish much more sharply between physical capacity and regulatory-ready capacity.
The two are not necessarily the same.
A new facility may add square footage and production slots to the market, but commercial value ultimately depends on whether that facility can support validated processes, withstand inspection and reliably manufacture an FDA-regulated product. That could create a meaningful premium for CDMOs and manufacturing organizations with established inspection records, experienced quality teams and proven commercial capabilities. It may also force developers to evaluate manufacturing partners earlier in the clinical lifecycle rather than treating commercial production as something to solve after pivotal data arrive.
The ITM announcement reinforces how costly that sequencing error can become. The COMPETE study met its primary endpoint, and the FDA has not asked the company for additional clinical or nonclinical data. Yet commercial progress is still dependent on resolving manufacturing-related issues.
Clinical success, in other words, is no longer sufficient evidence of commercial readiness.
The trend also helps explain why manufacturing infrastructure has become such a strategic focus for many of the largest radiopharmaceutical companies. Building isotope production systems, GMP facilities, analytical laboratories and distribution capabilities requires enormous capital investment. For smaller developers, outsourcing often remains the only practical route. But the more manufacturing becomes a source of regulatory uncertainty, the more valuable control over that infrastructure becomes.
Vertical integration cannot eliminate regulatory risk, but it can reduce dependence on external facilities whose quality systems, inspection history or operational problems may directly affect an approval timeline. That helps explain why companies across the sector are investing aggressively in their own manufacturing networks while still maintaining external partnerships. The objective is increasingly not just to secure capacity, but to secure control.
For larger companies, that infrastructure may ultimately become a competitive moat. A developer that controls isotope sourcing, manufacturing, quality systems and distribution can potentially manage its regulatory risk differently from one that depends on a fragmented external network. At the same time, the industry will continue to need CDMOs. The radiopharmaceutical pipeline is simply too large for every developer to vertically integrate. That means the strongest external manufacturers could become increasingly valuable as companies compete not just for space, but for proven regulatory execution.
The ITM decision is also notable because Lu-177 sits at the center of the most commercially mature segment of radiopharmaceutical therapy. The success of Lutathera and Pluvicto demonstrated that targeted radiopharmaceutical therapy can support major pharmaceutical products, but those launches also underscored the operational demands of producing and distributing radioactive medicines at commercial scale.
ITM-11 now represents another test of that infrastructure. The COMPETE trial evaluated ¹⁷⁷Lu-edotreotide against everolimus in patients with inoperable, progressive Grade 1 or Grade 2 GEP-NETs and met its primary endpoint, with ITM reporting a clinically and statistically significant improvement in progression-free survival.
The FDA has not challenged that clinical result, according to ITM. Yet the therapy still cannot be approved until the manufacturing-related issues are resolved. That makes the CRL significant beyond ITM itself.
As more Lu-177 products move through late-stage development, the isotope is increasingly becoming a test of whether the radiopharmaceutical industry can build not only enough capacity, but enough compliant commercial capacity. It is also notable that both Lantheus and ITM have now encountered manufacturing-related regulatory delays involving edotreotide products targeting neuroendocrine tumors. One is a Ga-68 diagnostic and the other a Lu-177 therapeutic, so the products and regulatory circumstances are different, but the parallel underscores how dependent the broader theranostic model is on manufacturing execution across both diagnostics and therapy.
For ITM, the immediate question is how significant the required remediation will be and how quickly the company and its external partners can address the FDA’s concerns. Because no additional clinical or nonclinical studies have been requested, the path forward may be more straightforward than it would be following a safety or efficacy-related CRL, but the company has not yet disclosed enough detail to determine the likely timeline. The same broader issue remains relevant for Telix and Lantheus. Telix has continued working through its Zircaix CMC requirements, while Lantheus remains dependent on remediation at its third-party manufacturing facility before LNTH-2501 can advance.
The more important market question is whether these cases remain isolated or begin to repeat as more radiopharmaceutical programs reach commercial review. If similar CMC deficiencies, Form 483 observations and facility-related CRLs continue appearing, then the industry may have to rethink where its most important bottleneck actually sits.
For years, the concern was that there would not be enough isotopes, manufacturing facilities or hot cells to support the expanding pipeline. The emerging concern is more nuanced. There may be plenty of capacity being built, but not all capacity is equal.
The radiopharmaceutical industry has spent billions of dollars preparing for commercial growth. Isotope producers are expanding. CDMOs are building new facilities. Nuclear pharmacies are adding capabilities. Drug developers are investing in vertical integration, and new manufacturing campuses are being developed across North America and Europe.
That infrastructure buildout remains necessary. But the recent experiences of ITM, Telix and Lantheus suggest that the sector is entering a stage where simply building more capacity will not be enough. The facilities supporting the next generation of radiopharmaceutical products will need to demonstrate that they can operate at scale, maintain product comparability, withstand inspection and consistently satisfy pharmaceutical manufacturing standards.
Behrenbruch’s comments following the Zircaix CRL captured the problem early: complex radiopharmaceutical supply chains are creating new regulatory challenges as the industry advances. Heino’s response at Lantheus showed how directly a third-party manufacturing problem can affect a sponsor even when the clinical product remains intact. And Cavey’s comments following the ITM-11 CRL now add another example, with the company maintaining confidence in its Phase 3 data while working through CMC and facility-related issues with the FDA and its partners.
Taken together, the message is becoming harder to ignore.
The radiopharmaceutical industry's next great infrastructure challenge may not be building enough factories or producing enough isotopes. It may be ensuring that the infrastructure already being built is capable of supporting the standards required for commercial approval.
For investors, developers and manufacturing partners, that distinction matters. Hot cells and isotope capacity will remain valuable, but validated processes, mature quality systems, experienced teams and successful regulatory inspections may become even more important.
The first phase of the radiopharmaceutical infrastructure boom was about capacity. The next phase will be about proving that capacity is truly commercial-ready.
